YOLFTbeta
FibroBiologics, Inc. Common Stock

FibroBiologics, Inc. Common Stock

FBLG · NASDAQ · Healthcare / Biotechnology

0.9271USD-0.04 (-4.21%)

Price History

Full chart

Market Stats

Previous Close0.9678
Open1.02
Day Range0.92 – 1.04
52-Week Range0.62 – 12.40
Volume35.43K
Market Cap9.46M
P/E (TTM)0.00
Forward P/E0.00
EPS-5.27
Dividend Yield0.00%
Beta1.68
50-Day Avg1.20
200-Day Avg3.01

About

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Peter O'Heeron
  • Employees15
  • Headquarters455 East Medical Center Boulevard, Houston, TX, United States, 77598, USA
  • Websitehttps://fibrobiologics.com

Leadership

  • Mr. Peter O'HeeronFounder, Chairperson & CEO · b. 1964
  • Dr. Hamid Khoja Ph.D.Chief Scientific Officer · b. 1970
  • Mr. Ruben A. Garcia J.D.General Counsel · b. 1977

Financials

Income Statement

Currency: USD2021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-00000
Cost of Revenue--94.00K437.00K573.00K832.00K
Gross Profit---94.00K-437.00K-573.00K-832.00K
Operating Expense--4.37M8.45M13.16M15.82M
Operating Income-1.17M-1.58M-4.47M-8.89M-13.74M-16.65M
EBITDA--1.58M-4.37M-15.90M-10.57M-17.61M
Net Income-1.17M-1.58M-5.12M-16.48M-11.16M-18.65M
R&D669.00K521.00K1.15M2.37M4.50M7.41M
Interest Expense-4.00K654.00K147.00K20.00K204.00K

Balance Sheet

Currency: USD2021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets-468.00K4.82M11.82M16.45M9.62M
Total Liabilities-1.76M8.82M10.57M13.71M3.46M
Total Equity--1.29M-4.00M1.25M2.73M6.16M
Cash-407.00K2.27M9.16M13.98M4.89M
Total Debt-1.30M7.52M1.75M10.55M2.41M
Net Debt-893.00K5.26M-7.42M-3.43M-2.48M

Cash Flow

Currency: USD2021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-1.17M-1.41M-4.07M-6.40M-11.90M-16.39M
Investing Cash Flow----495.00K-184.00K-262.00K
Financing Cash Flow1.17M1.82M5.92M13.79M16.91M7.57M
Capital Expenditure000495.00K184.00K262.00K
Free Cash Flow-1.17M-1.41M-4.07M-6.90M-12.09M-16.66M
FCF to OCF100.00%100.00%100.00%107.73%101.55%101.60%

Earnings

Report DateMay 29, 2024Aug 7, 2024Nov 12, 2024Mar 31, 2025May 14, 2025Aug 14, 2025Oct 31, 2025Feb 24, 2026May 1, 2026Jul 31, 2026Oct 30, 2026
EPS Estimate--1.80-1.73-0.09-2.50-0.12-2.30-2.00-1.35-0.93-0.63
EPS Actual-0.270.60-0.20-0.09-2.80-0.12-2.60-0.60-1.33-0.66-
Surprise-133.33%88.44%0.00%-12.00%0.00%-13.04%70.00%1.84%29.03%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap9.46M
Enterprise Value7.20M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.00
EPS-5.27
Book Value0.762
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-16.47M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-660.08%
Return on Assets-95.77%
Shares Outstanding6.96M
Shares Float5.74M
Beta1.68
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 12.50
  • Strong Buy
    1
  • Buy
    2

Ownership Breakdown

Institutions
14.87%
Insiders
13.74%
Retail / Other
71.39%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    67.67K1.02%
  • Fund Evaluation Group, LLC
    51.79K0.78%
  • Geode Capital Management, LLC
    29.61K0.44%
  • BlackRock Inc
    24.65K0.37%
  • Renaissance Technologies Corp
    16.00K0.24%
  • Vanguard Fiduciary Trust Co
    6.38K0.10%
  • UBS Group AG
    5.72K0.09%
  • Goss Wealth Management LLC
    8450.01%
  • Vanguard Global Advisers, LLC
    5360.01%
  • Tower Research Capital LLC
    4600.01%
  • Western Wealth Management, LLC
    2000.00%
  • Royal Bank of Canada
    1860.00%
  • Islay Capital Management, LLC
    1690.00%
  • Advisor Group Holdings, Inc.
    1540.00%
  • Coconut Grove Bank
    1000.00%
  • BNP Paribas Arbitrage, SA
    660.00%
  • Hanson Mcclain Inc
    130.00%

Top Fund Holders

  • Fidelity Extended Market Index
    24.38K0.86%
  • Fidelity Series Total Market Index
    2.57K0.09%
  • Fidelity Total Market Index
    2.27K0.08%

Stock Splits

  • Mar 30, 20261:20